Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific and Biocept have signed a non-binding memorandum of understanding to collaborate commercially, Biocept said today.

The companies initially plan to validate Thermo Fisher's Oncomine next-generation sequencing liquid biopsy panels in Biocept's CLIA-certified laboratory.

Following that and other requirements, Thermo Fisher intends to designate Biocept as a Center of Excellence for oncology liquid biopsy initiatives and to pursue commercial opportunities with the company.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.